Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer.
Unraveling complexity. Harnessing insights.
Targeted therapies only work when inhibiting the target pathway disrupts the oncogenic process. Celcuity’s platform provides unparalleled insights into oncogenic pathways by analyzing live patient tumor cells.
We harness these insights to develop new targeted therapies for cancer patients.